GRAZAX^® is a new tablet for treating grass pollen allergy. In April 2004, ALK-Abelló presented the results of the first efficacy study of the tablet, which provided ”proof of concept”. In June 2004, a registration application was filed with the Swedish authorities. In January and October 2005, ALK-Abelló published further positive clinical data for GRAZAX^®. The company expects to gain authorization to market GRAZAX^® in time for patients suffering from grass pollen allergy to benefit from the new vaccine from the end of 2006.